Trending

Non-small cell lung cancer

Roche’s Tecentriq combo extends life in advanced NSCLC

Roche’s Tecentriq combo extends life in advanced NSCLC

Roche has announced that its phase 3 IMpower130 study met its co-primary endpoints of overall survival and progression-free survival in non-small cell lung cancer (NSCLC).

X

Roche’s Tecentriq combo extends life in advanced NSCLC

https://pharmaphorum.com/news/roches-tecentriq-combo-advanced-nsclc/

Evolving immunotherapy strategies in NSCLC

Evolving immunotherapy strategies in NSCLC

Status of immunotherapies in non-small cell lung cancer (NSCLC).

X

Evolving immunotherapy strategies in NSCLC

https://pharmaphorum.com/views-and-analysis/evolving-immunotherapy-strategies-nsclc/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com